Low-Dose Lithium for Stage IV Cancer
Also known as: Lithium orotate, Lithium aspartate, Microdose lithium
GSK3β modulation by lithium affects Wnt/β-catenin signaling and may influence cancer stem cell biology.
Mechanism of Action
Lithium inhibits GSK3β, activating Wnt/β-catenin — which has complex, context-dependent effects in cancer (pro-tumorigenic in some types, anti-tumorigenic in others). It also sensitizes cancer cells to radiation therapy and may reduce chemotherapy-induced cognitive dysfunction.
General mechanism: GSK3β inhibitor. Autophagy inducer (IP3 pathway). BDNF/GDNF enhancer. Neuroprotective at microdoses.
Current Evidence
Lithium reduces radiation-induced cognitive damage (neuroprotection during brain radiation). Cancer stem cell effects are context-dependent. Used to prevent chemotherapy-induced neutropenia.
Clinical Status: Used clinically for neutropenia prevention. Neuroprotection during brain radiation studied.
Safety Profile
Microdose (<1mg): very safe. Standard dose (600-1200mg): renal, thyroid toxicity requiring monitoring. Narrow therapeutic index at psychiatric doses.
Key Research Questions
- Can lithium protect cognition during whole-brain radiation?
- In which cancer types does GSK3β inhibition help vs harm?